Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on March 6, 2018. The filing addresses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
Departure of Director: Dean Slagel, a member of the Board of Directors, resigned effective March 7, 2018. Mr. Slagel was the longest-tenured director, having joined the Board in 2005 in connection with Esperante AB's initial investment. The Company stated that the resignation was not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing does not contain guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the director's departure.
Investor Verification Checklist
- Verify the correct registrant name is Cara Therapeutics, Inc., not Tvardi Therapeutics, Inc.
- Confirm the effective date of Dean Slagel's resignation (March 7, 2018).
- Review subsequent filings to determine if a replacement director was appointed.
- Check for any related proxy statements or 10-Q/10-K filings for financial context not included in this 8-K.